Effects of notoginsenoside on the expressions of nerve growth factor and brain-derived neurotrophic factor in spinal cord of rats with transected injury

CH Huang,TH Wang,Q Li
DOI: https://doi.org/10.3321/j.issn:1673-8225.2007.41.020
2007-01-01
Abstract:Aim: Both of endogenous nerve growth factor and brain-derived neurotrophic factor are in the family of neurenergen, and play an important role in the development of nervous system and function of normal neuron. This study was aimed to explore the effect of notoginsenoside on the expressions of nerve growth factor and brain-derived neurotrophic factor in spinal cord following transected injury. Methos: The experiment was carried out in the Institute of Neuroscience of Kunming Medical College from June to September 2005. 1 Totally 72 healthy female SD rats of clean grade and with the body mass of (200±20) g were selected and notoginsenoside was bought from Yunnan Phytopharmaceutical Co., Ltd. 2 The rats were divided into four groups at random, sham operation group, transected spinal cord injury group, transected spinal cord injury and saline (0.5 mL/dose, peritoneal, injection)therapy group as well as transected spinal cord injury and notoginsenoside (100 mg/kg/dose) therapy group with 18 in each group. Dura mate of spinal cord was cut at T10 in rats of the sham operation group, but spinal cord was not injured. Administration was performed at minute 30, hours 4, 24, 48 and 72 after operation in the latter two groups. 3 The L1-2 spinal segments were removed out and made into frozen sections at days 3, 7 and 21 after operation (n =6), and then stained by ABC method of immunohistochemistry. Positive neurons of nerve growth factor and brain-derived neurotrophic factor in the ventral horn of spinal cord were counted. Histochemical and pathological changes of spinal cord were observed by conventional hematoxylin-eosin stain. Results: A total of 72 rats were involved in the result analysis. 1 Pathologic changes of spinal cord were apparent after transected injury such as necrosis of neural degeneration, inflammatory infiltration and so on. 2 The expression of nerve growth factor proteins was observed in normal spinal cord, mainly distributed in the cytoplasm of neurons and nucleus of glial cells. The expression of nerve growth factor was increased significantly at day 7 and still higher after spinal cord injury at day 21 than that of sham operation group (P < 0.05). Notoginsenoside promoted significantly the expression of nerve growth factor and its expression was obviously higher than that of other groups at days 3 and 7 (P < 0.05). The expression of nerve growth factor was downregulation at day 21, however, it was also exceeded to the sham operation group (P < 0.05). 3 The brain-derived neurotrophic factor proteins mainly distributed in the cytoplasm of motor neurons and there were not observed in glial cells. The expression of brain-derived neurotrophic factor was very low in normal spinal cord. The expression of brain-derived neurotrophic factor was increased significantly at day 7 after spinal cord injury (P < 0.05), but it was downregulation and no significant difference compared with that of normal spinal cord at day 21 (P > 0.05). Notoginsenoside promoted significantly the expression of brain-derived neurotrophic factor that was obviously higher than that of the control group at days 3, 7 and 21 (P < 0.05). Conclusion: Notoginsenoside can alleviate the secondary damage and promote significantly the expressions of endogenous nerve growth factor and brain-derived neurotrophic factor both in quantity and time after spinal cord injury. The findings elucidated that notoginsenoside is beneficial to the early repair of spinal cord injury.
What problem does this paper attempt to address?